AMGNCongressional Stock Trades
Amgen Inc
Biological Products, (No Diagnostic Substances)
Congressional stock trades in Amgen Inc (AMGN) from House and Senate STOCK Act filings. See which members of Congress bought or sold, disclosed amounts, and filing dates.
Total Trades
36
Politicians Trading
13
Last Traded
Aug 26, 2026
Trading History
| Politician | Notified | Traded | Type | Amount | Change |
|---|---|---|---|---|---|
| David TaylorR | Sep 5, 2026 | Aug 26, 2026 | Sell | $1,001 - $15,000 | -12.42% |
| David TaylorR | Sep 5, 2026 | Aug 26, 2026 | Sell | $1,001 - $15,000 | -12.42% |
| Ro KhannaD | Aug 7, 2026 | Jul 20, 2026 | Sell | $1,001 - $15,000 | +5.90% |
| Ro KhannaD | Jun 9, 2026 | May 15, 2026 | Sell | $15,001 - $50,000 | +18.19% |
| Ro KhannaD | May 11, 2026 | Apr 24, 2026 | Sell | $15,001 - $50,000 | +11.93% |
| David TaylorR | Mar 6, 2026 | Feb 26, 2026 | Sell | $1,001 - $15,000 | +1.67% |
| David TaylorR | Feb 2, 2026 | Jan 29, 2026 | Sell | $1,001 - $15,000 | +12.45% |
| David TaylorR | Dec 5, 2025 | Dec 3, 2025 | Sell | $1,001 - $15,000 | +11.65% |
| David TaylorR | Dec 5, 2025 | Dec 3, 2025 | Sell | $1,001 - $15,000 | +11.65% |
| Lisa C. McClainR | Oct 22, 2025 | Sep 25, 2025 | Sell | $1,001 - $15,000 | +42.21% |
| Daniel MeuserR | Aug 20, 2025 | Feb 11, 2025 | Sell | $1,001 - $15,000 | +30.00% |
| Jefferson ShreveR | Jun 22, 2025 | May 12, 2025 | Sell | $15,001 - $50,000 | +40.36% |
| Robert BresnahanR | May 8, 2025 | Apr 8, 2025 | Sell | $1,001 - $15,000 | +37.60% |
| Emily RandallD | Feb 11, 2025 | Jan 6, 2025 | Sell | $1,001 - $15,000 | +49.14% |
Price History
About Amgen Inc
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.